Table 3.

Statin based trials in subjects with coronary heart disease: trials with clinical CHD end points

		Lipid lowering (% change)
	Treatment (duration)	Chol	Trig	HDL	Reduction in CHD end point
Scandinavian Simvastatin Survival Study (4S) (1994)w10	Simvastatin (5.4 years)	−25	−10	+8	↓34%; ↓42% CHD death
Cholesterol and Recurrent Events (CARE) (1996)w11	Pravastatin (5 years)	−20	−14	+5	↓24%; ↓20% CHD death
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) (1998)w12	Pravastatin (6 years)	−18	−11	+6	↓24%; ↓24% CHD death
Atorvastatin versus Revascularization Treatment (AVERT) (1999)w13	Atorvastatin v angioplasty + other lipid treatment (1.5 years)	−31	−11	+8	↓36% “ischaemic events” (angioplasty, CABG, hospitalisation for angina)
Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) (2000)w14	Pravastatin (6.2 years)	−18	−11	+4	↓26%
Fluvastatin in Acute Myocardial Infarction (FLORIDA) (2002)w15	Fluvastatin (1 year)	−23 (LDL)			NS
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes (MIRACL) (2001)w16	Atorvastatin (16 weeks)	−27	−16	+4	NS (only ↓re-hospitalisation for symptomatic myocardial ischaemia)
Heart Protection Study (HPS) (2002)w17	Simvastatin (5 years)	−20	−16	+3	↓24%
Lescol Intervention Prevention Study (LIPS) (2002)w18	Fluvastatin (3.9 years)	-27 (LDL)	−22	+22	↓26% (cardiac death, MI or revascularisation)

NS, non-significant/no change.

Baseline mean cholesterol 5.3 –6.9 mmol/l.